Fimepinostat (CUDC‐907) in patients with relapsed/refractory diffuse large B cell and high‐grade B‐cell lymphoma: report of a phase 2 trial and exploratory biomarker analyses
暂无分享,去创建一个
Mariano J. Alvarez | Sonali M. Smith | A. Califano | Y. Oki | M. Alvarez | R. Martell | Yao Shen | R. Ramchandren | S. Iyer | S. Barta | I. Micallef | D. Landsburg | D. Stevens | C. Batlevi | K. Kelly | G. Bosker | R. V. von Roemeling | J. Parker | E. Martinez | R. Soikes
[1] S. Schuster,et al. TIME‐TO‐RESPONSE FOR PATIENTS WITH RELAPSED/REFRACTORY AGGRESSIVE B CELL NON‐HODGKIN LYMPHOMA TREATED WITH POLATUZUMAB‐BASED THERAPY , 2021, Hematological Oncology.
[2] J. Shah,et al. A Six-Protein Activity Signature Defines Favorable Response to Selinexor Treatment for Patients with Diffuse Large B-Cell Lymphoma (DLBCL) , 2020 .
[3] M. Karjalainen‐Lindsberg,et al. Molecular background delineates outcome of double protein expressor diffuse large B-cell lymphoma. , 2020, Blood advances.
[4] G. Salles,et al. Single-agent activity of phosphatidylinositol 3-kinase inhibition with copanlisib in patients with molecularly defined relapsed or refractory diffuse large B-cell lymphoma , 2020, Leukemia.
[5] M. Dimopoulos,et al. Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma. , 2019, The New England journal of medicine.
[6] J. Rhodes,et al. Small-Molecule Inhibitors for the Treatment of Diffuse Large B Cell Lymphoma , 2018, Current Hematologic Malignancy Reports.
[7] S. Schuster,et al. Outcomes of patients with MYC-expressing aggressive B cell non-Hodgkin lymphomas who fail two or more lines of therapy. , 2018 .
[8] Jeffrey A Jones,et al. Duvelisib, a novel oral dual inhibitor of PI3K-δ,γ, is clinically active in advanced hematologic malignancies. , 2018, Blood.
[9] Mariano J. Alvarez,et al. Quantitative assessment of protein activity in orphan tissues and single cells using the metaVIPER algorithm , 2018, Nature Communications.
[10] I. Flinn,et al. CUDC-907 in relapsed/refractory diffuse large B-cell lymphoma, including patients with MYC-alterations: results from an expanded phase I trial , 2017, Haematologica.
[11] D. Potvin,et al. A phase 2 study of mocetinostat, a histone deacetylase inhibitor, in relapsed or refractory lymphoma , 2017, British journal of haematology.
[12] A. Fattaey,et al. Dual HDAC and PI3K Inhibitor CUDC-907 Downregulates MYC and Suppresses Growth of MYC-dependent Cancers , 2016, Molecular Cancer Therapeutics.
[13] Ryan D. Morin,et al. Phase 2 study of panobinostat with or without rituximab in relapsed diffuse large B-cell lymphoma. , 2016, Blood.
[14] Mariano J. Alvarez,et al. Network-based inference of protein activity helps functionalize the genetic landscape of cancer , 2016, Nature Genetics.
[15] A. Califano,et al. Network-based inference of protein activity helps functionalize the genetic landscape of cancer , 2016, Nature Genetics.
[16] I. Flinn,et al. Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trial. , 2016, The Lancet. Oncology.
[17] D. Landsburg. Management of Patients with MYC-Altered Lymphomas , 2016, Current Hematologic Malignancy Reports.
[18] J. Olson,et al. HDAC and PI3K Antagonists Cooperate to Inhibit Growth of MYC-Driven Medulloblastoma. , 2016, Cancer cell.
[19] L. Medeiros,et al. B-cell lymphomas with concurrent MYC and BCL2 abnormalities other than translocations behave similarly to MYC/BCL2 double-hit lymphomas , 2015, Modern Pathology.
[20] J. Briones,et al. MYC protein expression and genetic alterations have prognostic impact in patients with diffuse large B-cell lymphoma treated with immunochemotherapy , 2013, Haematologica.
[21] A. Rosenwald,et al. MYC diffuse large B-cell lymphoma is not salvaged by classical R-ICE or R-DHAP followed by BEAM plus autologous stem cell transplantation , 2012 .
[22] S. Barrans,et al. Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] Mariano J. Alvarez,et al. A human B-cell interactome identifies MYB and FOXM1 as master regulators of proliferation in germinal centers , 2010, Molecular systems biology.
[24] R. Gascoyne,et al. MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy. , 2009, Blood.
[25] L. Penn,et al. Reflecting on 25 years with MYC , 2008, Nature Reviews Cancer.
[26] Soyoung Lee,et al. FoxO transcription factors suppress Myc-driven lymphomagenesis via direct activation of Arf. , 2007, Genes & development.
[27] Sigrid Stroobants,et al. Revised response criteria for malignant lymphoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] Kathryn A. O’Donnell,et al. The c-Myc target gene network. , 2006, Seminars in cancer biology.
[29] Adam A. Margolin,et al. Reverse engineering of regulatory networks in human B cells , 2005, Nature Genetics.
[30] R. Medema,et al. Myc‐induced proliferation and transformation require Akt‐mediated phosphorylation of FoxO proteins , 2004, The EMBO journal.
[31] M. Ashburner,et al. Gene Ontology: tool for the unification of biology , 2000, Nature Genetics.
[32] L. Staudt,et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. , 2004, Blood.
[33] Heekuck Oh,et al. Neural Networks for Pattern Recognition , 1993, Adv. Comput..